Herpes vector-mediated expression of proenkephalin reduces bone cancer pain.
We examined whether a herpes simplex virus vector that expresses human proenkephalin could be used to attenuate nociception in a model of bone cancer pain in mice. Osteolytic sarcoma cells were implanted into the medullary space of the right femur, followed by a subcutaneous inoculation of a replication-defective herpes simplex virus vector expressing human proenkephalin (vector SHPE) or a lacZ-expressing control vector (vector SHZ). SHPE-inoculated mice demonstrated a significant, naltrexone-reversible decrease in pain-related behavior assessed during open-field motor activity. These results suggest that gene transfer with an enkephalin-expressing vector may be used to treat pain resulting from cancer in bone.
Goss
James R
JR
Department of Neurology, University of Pittsburgh School of Medicine, Biomedical Science Tower, Pittsburgh, PA 15213, USA.
Harley
Cara F
CF
Mata
Marina
M
O'Malley
Mark E
ME
Goins
William F
WF
Hu
XiaoPing
X
Glorioso
Joseph C
JC
Fink
David J
DJ
D000818:Animals; D001859:Bone Neoplasms / Q000628:therapy*; D004745:Enkephalins / Q000235:genetics*; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D012516:Osteosarcoma / Q000628:therapy*; D010166:Palliative Care / Q000379:methods*; D011498:Protein Precursors / Q000235:genetics*; D012513:Sarcoma, Experimental / Q000628:therapy; D018139:Simplexvirus / Q000235:genetics*
D004745:Enkephalins; D011498:Protein Precursors; C029992:proenkephalin